Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
12 Marzo 2024 - 1:00PM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
testing, today announced new data being presented on its
personalized and tumor-informed molecular residual disease (MRD)
test, Signatera™, and hereditary cancer test, Empower™, at the 2024
Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s
Cancer taking place March 16-18, 2024.
A total of seven abstracts will be presented, including two oral
presentations and five poster presentations. The presentations will
feature new data highlighting Signatera’s predictive and prognostic
utility in ovarian cancer and other gynecologic malignancies.
“On the heels of receiving Medicare coverage for Signatera in
ovarian cancer and for breast cancer in the neoadjuvant setting, we
are thrilled to share new Signatera and Empower data with the
gynecologic oncology community,” said Adam ElNaggar, MD, medical
director of oncology at Natera. “We believe this momentum is
indicative of the growing clinical value our tests provide for
patients across the continuum of gynecologic cancer care, and
demonstrate our continued leadership in MRD.”
Below is the full list of Signatera and Empower data
presentations at the SGO Annual Meeting.
Oral Presentations:
- Focused Plenary I: The Science to Drive Purpose | March 16,
2:15 - 3:30 PM | Presenter: Anne Knisely, MD | Ovarian Cancer
Prognostic implications of minimal residual disease detection by
second look laparoscopy and circulating tumor DNA (ctDNA) in
patients with ovarian cancer after frontline therapy
- Focused Plenary IV: ctDNA: Molecular Mirrors & Markers |
March 17, 1:45 - 2:45 PM | Presenter: Mike Shalamov | Gynecologic
Cancers Utility of ctDNA as an early predictive biomarker of
response to radiation in gynecologic malignancies
Poster Presentations:
- Poster #1241 | Session 1 | March 17, 1:15 - 2:45 PM |
Presenter: Michael Toboni, MD | Ovarian Cancer
PARPi response monitoring using personalized ctDNA testing in
patients with ovarian cancer
- Poster #1242 | Session 1 | March 17, 1:15 - 2:45 PM |
Presenter: Peter W. Ketch, MD | Uterine Cancer Treatment
Monitoring Utilizing ctDNA-based MRD Detection in Early Stage
Uterine Cancer
- Poster #1243 | Session 1 | March 17, 1:15 - 2:45 PM |
Presenter: Michael Toboni, MD | Uterine Cancer Personalized
ctDNA analysis used for ctDNA detection and response monitoring in
patients with advanced or recurrent uterine cancer
- Poster #1274 | Session 1 | March 17, 1:15 - 2:45 PM |
Presenter: Floortje Backes, MD | Endometrial and Ovarian Cancer
Utility of ctDNA in assessment of treatment response in patients
with Recurrent/Metastatic Endometrial Cancer and
Recurrent/Platinum-Resistant Ovarian Cancer
- Poster #1181 | Session 1 | March 17, 1:15 - 2:45 PM |
Presenter: Sarah Lee, MD | Pan-cancer Diagnostic yield and
characteristics of germline-positive genetic testing ordered by
obstetricians and gynecologists in female patients with a personal
history of cancer
About Signatera
Signatera is a personalized, tumor-informed, molecular residual
disease test for patients previously diagnosed with cancer.
Custom-built for each individual, Signatera uses circulating tumor
DNA to detect and quantify cancer left in the body, identify
recurrence earlier than standard of care tools, and help optimize
treatment decisions. The test is available for clinical and
research use and is covered by Medicare for patients with
colorectal cancer, breast cancer, ovarian cancer and muscle
invasive bladder cancer, as well as for immunotherapy monitoring of
any solid tumor. Signatera has been clinically validated across
multiple cancer types and indications, with published evidence in
more than 50 peer-reviewed papers.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 180 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
whether the results of clinical or other studies will support the
use of our product offerings, the impact of results of such
studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in "Risk
Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240312178257/en/
Investor Relations: Mike Brophy, CFO Natera, Inc. 510-826-2350
investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications Natera,
Inc. pr@natera.com
Grafico Azioni Natera (NASDAQ:NTRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Natera (NASDAQ:NTRA)
Storico
Da Giu 2023 a Giu 2024